Physician profile
Daniel Marin
NPI 1396920161
$2,145.55
in general payments reported to CMS, 2019-2025
25 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $740 · 2020: $204 · 2021: $859 · 2022: $52.67 · 2023: $141 · 2024: $46.09 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $290.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $425.00 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $262.48 | 2021 | |
| Biodelivery Sciences International, INC. | $204.38 | 2021 | |
| Qol Medical, LLC | $191.20 | 2019-2023 | Sucraid |
| Amniox Medical, INC. | $125.00 | 2019 | |
| Boston Scientific Corporation | $112.54 | 2019 | |
| Abbvie INC. | $94.09 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.17 | 2019-2020 | |
| Electronic Waveform Lab, INC. | $80.28 | 2025 | |
| Relievant Medsystems, INC. | $78.89 | 2021 | |
| Interventional Pain Technologies INC. | $75.48 | 2021 | |
| Redhill Biopharma INC. | $52.23 | 2020-2023 | Movantik, Talicia, Aemcolo |
| Depuy Synthes Sales INC. | $50.97 | 2024-2025 | Orthovisc, Monovisc |
| Stimwave Technologies Incorporated | $42.23 | 2019 | |
| Spinal Simplicity, LLC | $37.62 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $36.73 | 2019 | |
| Janssen Biotech, INC. | $26.88 | 2019 | |
| Nestle Healthcare Nutrition INC. | $26.10 | 2023 | |
| Horizon Therapeutics Plc | $25.04 | 2021 | |
| Alfasigma USA, INC. | $23.55 | 2021 | |
| Trice Medical, INC. | $20.04 | 2023 | |
| Evoke Pharma, INC. | $19.23 | 2023 | Gimoti |
| Shire North American Group INC | $18.38 | 2019 | |
| Curonix LLC | $17.55 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Takeda Pharmaceuticals U.S.A., INC. | $16.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Marin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.